Whalesbook
📉 The Financial Deep Dive
CORONA Remedies Limited showcased strong financial performance in its third quarter and nine months ended December 31, 2025. Revenue for Q3 FY'26 grew by a significant 15% year-on-year (YoY) to ₹342 crores, up from ₹298 crores in Q3 FY'25. This top-line expansion was complemented by a 20% YoY increase in EBITDA to ₹83 crores, leading to an improvement in EBITDA margins by 100 basis points (bps) to a healthy 24.3%. Profit After Tax (PAT), after accounting for one-time impacts, surged by 24% YoY to ₹56 crores, indicating enhanced profitability.
For the cumulative nine-month period of FY'26, CORONA Remedies reported revenue of ₹1,050 crores, a 16% increase YoY, surpassing its guided 15% growth. EBITDA for 9M FY'26 rose approximately 25% YoY to ₹231 crores, with margins expanding by 140 bps to 22%. Adjusted PAT for the nine months saw a substantial 31% YoY jump to ₹154 crores, considerably exceeding the guided 20% growth. The company highlighted its strong financial health, with annualized Return on Equity (ROE) at 31% and Return on Capital Employed (ROCE) at 48% for 9M FY'26. Its operational efficiency is further underscored by an Operating Cash Flow (OCF) to EBITDA conversion rate of 86%, confirming its status as a net cash surplus entity.
❓ The "Grill": Analyst Queries and Management Responses
During the earnings call, analysts probed CORONA Remedies on its outperformance compared to the broader Indian Pharmaceutical Market (IPM), where the company registered 18.9% growth in Q3 FY'26 against IPM's 9.6%, helping it climb two ranks in market share. Management also addressed the impact of adding 600 medical representatives over three years, acknowledging the rise in employee costs but emphasizing the long-term strategy for margin improvement through scale. While CORONA Remedies maintains competitive profitability, it operates at slightly lower EBITDA margins compared to some peers, a point management addressed by highlighting their strategic focus on market share expansion and value-driven growth rather than solely margin maximization.
🚀 Risks & Outlook
Management reiterated its annual guidance, projecting 15% revenue growth and 20% PAT growth, expecting to continue achieving mid-teen revenue growth and high-teen PAT growth. Key growth drivers for the upcoming periods include the strategic increase in market share within chronic and semi-chronic therapy areas, propelled by new product launches. The significant portfolio acquired from Bayer is poised to commence commercialization in Q4 FY'26 with the launch of Noklot Plus, acting as a major catalyst. Furthermore, the EAEU GMP accreditation for its Gujarat facility opens access to a USD 25 billion market across five EAEU countries via a B2B model, although international growth is viewed as a 3-5 year gestation strategy. The planned launch of a GLP-1 injectable, Wyntide, in March 2026, is another key initiative targeting the off-patent injectable market. The company is also investing in manufacturing capacity, anticipating the need for a new plant by FY'28-FY'29, and is actively evaluating two further brand acquisitions.